{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:34:47Z","timestamp":1793331287133,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:00:00Z","timestamp":1569456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:00:00Z","timestamp":1569456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s40264-019-00861-y","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T23:26:12Z","timestamp":1569540372000},"page":"1487-1498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports"],"prefix":"10.1007","volume":"42","author":[{"given":"Rika","family":"Wakao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2604-2810","authenticated-orcid":false,"given":"Henric","family":"Taavola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovisa","family":"Sandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiko","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Soejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4595-230X","authenticated-orcid":false,"given":"G. Niklas","family":"Nor\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,26]]},"reference":[{"issue":"3","key":"861_CR1","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10618-006-0052-8","volume":"14","author":"GN Nor\u00e9n","year":"2007","unstructured":"Nor\u00e9n GN, Orre R, Bate A, Edwards IR. Duplicate detection in adverse drug reaction surveillance. Data Min Knowl Discov. 2007;14(3):305\u201328. \nhttps:\/\/doi.org\/10.1007\/s10618-006-0052-8\n\n.","journal-title":"Data Min Knowl Discov."},{"issue":"10","key":"861_CR2","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/pds.4285","volume":"26","author":"K Juhlin","year":"2017","unstructured":"Juhlin K, Star K, Nor\u00e9n GN. A method for data-driven exploration to pinpoint key features in medical data and facilitate expert review. Pharmacoepidemiol Drug Saf. 2017;26(10):1256\u201365. \nhttps:\/\/doi.org\/10.1002\/pds.4285\n\n.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"861_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57\u201369. \nhttps:\/\/doi.org\/10.1177\/0962280211403604\n\n.","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"861_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","volume":"37","author":"T Bergvall","year":"2014","unstructured":"Bergvall T, Nor\u00e9n GN, Lindquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37(1):65\u201377. \nhttps:\/\/doi.org\/10.1007\/s40264-013-0131-x\n\n.","journal-title":"Drug Saf"},{"issue":"11","key":"861_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/pds.1071","volume":"14","author":"LC Koo","year":"2005","unstructured":"Koo LC, Clark JA, Quesenberry CP, Higenbottam T, Nyberg F, Wolf MK, et al. National differences in reporting \u2018pneumonia\u2019 and \u2018pneumonia interstitial\u2019: an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions. Pharmacoepidemiol Drug Saf. 2005;14(11):775\u201387. \nhttps:\/\/doi.org\/10.1002\/pds.1071\n\n.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"861_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/pds.3998","volume":"25","author":"L Pinheiro","year":"2016","unstructured":"Pinheiro L, Blake K, Januskiene J, Yue Q-Y, Arlett P. Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance. Pharmacoepidemiol Drug Saf. 2016;25(6):705\u201312. \nhttps:\/\/doi.org\/10.1002\/pds.3998\n\n.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"861_CR7","unstructured":"European Medicines Agency. Medicines. 2018. \nhttps:\/\/www.ema.europa.eu\/en\/medicines\n\n. Accessed 29 Nov 2018."},{"key":"861_CR8","unstructured":"Pharmaceuticals and Medical Devices Agency. PMDA labels [in Japanese]. 2019. \nhttps:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuSearch\/\n\n. Accessed 6 Mar 2019."},{"key":"861_CR9","doi-asserted-by":"publisher","unstructured":"OECD. The burden of cardiovascular disease and diabetes. In: Cardiovascular disease and diabetes: policies for better health and quality of care. Paris: OECD Publishing; 2015. p. 31\u201351. \nhttps:\/\/doi.org\/10.1787\/9789264233010-5-en\n\n.","DOI":"10.1787\/9789264233010-5-en"},{"key":"861_CR10","unstructured":"US FDA. Table of pharmacogenomic biomarkers in drug labeling. Last updated 06\/2019. \nhttps:\/\/www.fda.gov\/media\/124784\/download\n\n. Accessed 5 Aug 2019."},{"key":"861_CR11","unstructured":"PMDA. Early detection of drug-induced serious skin disorders. In: PMDA alert for proper use of drugs. Tokyo: PMDA; 2012. \nhttps:\/\/www.pmda.go.jp\/files\/000153436.pdf\n\n. Accessed 2 Dec 2018."},{"key":"861_CR12","doi-asserted-by":"publisher","unstructured":"OECD. Computed tomography (CT) exams (indicator). 2018. \nhttps:\/\/doi.org\/10.1787\/3c994537-en\n\n. Accessed 27 Nov 2018.","DOI":"10.1787\/3c994537-en"},{"issue":"1","key":"861_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40264-016-0456-3","volume":"40","author":"RE Chandler","year":"2017","unstructured":"Chandler RE, Juhlin K, Fransson J, Caster O, Edwards IR, Nor\u00e9n GN. Current safety concerns with human papillomavirus vaccine: a cluster analysis of reports in VigiBase\u00ae. Drug Saf. 2017;40(1):81\u201390. \nhttps:\/\/doi.org\/10.1007\/s40264-016-0456-3\n\n.","journal-title":"Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-019-00861-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-019-00861-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-019-00861-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T23:37:51Z","timestamp":1600990671000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-019-00861-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,26]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["861"],"URL":"https:\/\/doi.org\/10.1007\/s40264-019-00861-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,26]]},"assertion":[{"value":"26 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Rika Wakao, Henric Taavola, Lovisa Sandberg, Eiko Iwasa, Saori Soejima, Rebecca Chandler and G. Niklas Nor\u00e9n have no conflicts of interest that are directly relevant to the content of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}